During the corresponding time, Surmodics Inc saw a revenue deteriorated by -2.55 % year on year, sequentially revenue grew by 5.28 %. While revenue at the Surmodics Inc 's corporate clients
Surmodics Inc's Comment on Sales, Marketing and Customers
The company operates in the medical device industry, specializing in vascular intervention medical devices and performance coatings. Its Medical Device segment offers proprietary vascular intervention products and licenses performance coatings to medical device manufacturers. The vascular intervention products address large, under-penetrated markets and unmet clinical needs, including drug-coated balloons for peripheral artery disease (PAD), mechanical thrombectomy devices for clot removal in peripheral arteries and veins, and radial access devices for treating stenosed arteries from the wrist to the foot. Customers primarily consist of medical device manufacturers that license the company's performance coating technologies for incorporation into their devices.
Eden Prairie, Minn. - Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, has announced a significant achievement in the healthcare sector. The company has been awarded a group purchasing agreement for its innovative thrombectomy products with Premier, Inc. The agreement is set to take effect on June 1, 2024. Premier, Inc. is a well-established healthcare improvement organization and one of the largest group purchasing organizations (GPOs) in the United States. It boasts a vast network of hospitals and healthcare providers that collectively focus on improving healthcare quality while reducing costs. This new partnership marks a milestone in Surmodics’ ...
Surmodics Revolutionizes Medical Device Coating Technology with Preside, Enhancing Neurovascular Procedures EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), the renowned pioneer in medical device coating technologies, has made yet another groundbreaking advancement in the field with the commercial launch of its cutting-edge hydrophilic medical device coating technology, Preside hydrophilic coatings. Aimed at a broader range of complex device applications, Preside hydrophilic coatings provide unparalleled lubricity and durability, bolstering distal access for neurovascular procedures. Surmodics has long been recognized as a global leader in medical device coating technologies, and the introductio...
Surmodics Inc’s Comment on Sales, Marketing and Customers
The company operates in the medical device industry, specializing in vascular intervention medical devices and performance coatings. Its Medical Device segment offers proprietary vascular intervention products and licenses performance coatings to medical device manufacturers. The vascular intervention products address large, under-penetrated markets and unmet clinical needs, including drug-coated balloons for peripheral artery disease (PAD), mechanical thrombectomy devices for clot removal in peripheral arteries and veins, and radial access devices for treating stenosed arteries from the wrist to the foot. Customers primarily consist of medical device manufacturers that license the company's performance coating technologies for incorporation into their devices.
Sources:
Surmodics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Surmodics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Surmodics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
56.69 %